Valneva SE is a pharmaceutical company based in France with a focus on developing life-saving vaccines. With a medium risk ESG score of 27.1, the company has a portfolio of vaccines for travelers and is actively involved in the development, manufacturing, and distribution of a COVID-19 vaccine. Their revenue mainly comes from product sales across various segments including commercialized vaccines, vaccine candidates, and technologies. Valneva SE is committed to sustainability and good governance practices in the pharmaceutical industry.